期刊
JOURNAL OF CONTROLLED RELEASE
卷 173, 期 -, 页码 51-58出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2013.10.031
关键词
Chain-like nanoparticle; Targeting; Cancer metastasis; Nanochains; Radiofrequency-triggered drug release
资金
- National Cancer Institute [R01CA177716, R25CA148052]
- Clinical and Translational Science Collaborative of Cleveland from the National Center for Advancing Translational Sciences component of the National Institutes of Health [UL1TR000439]
- Case Comprehensive Cancer Center [P30CA043703]
- Ohio Cancer Research Associates
- NIH [T32EB007509]
While potent cytotoxic agents are available to oncologists, the clinical utility of these agents is limited due to their non-specific distribution in the body and toxicity to normal tissues leading to use of suboptimal doses for eradication of metastatic disease. Furthermore, treatment of micrometastases is impeded by several biobarriers, including their small size and high dispersion to organs, making them nearly inaccessible to drugs. To circumvent these limitations in treating metastatic disease, we developed a multicomponent, flexible chain-like nanoparticle (termed nanochain) that possesses a unique ability to gain access to and be deposited at micrometastatic sites. Moreover, coupling nanochain particles to radiofrequency (RF)-triggered cargo delivery facilitated widespread delivery of drug into hard-to-reach cancer cells. Collectively, these features synergistically facilitate effective treatment and ultimately eradication of micrometastatic disease using a low dose of a cytotoxic drug. (C) 2013 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据